(Q36428225)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Resistance to somatostatin analogs in acromegaly: an evolving concept? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

M Gola

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

S Bonadonna

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

G Amato

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

A Giustina

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

86-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf03349183

18 January 2020

exact match

0 references

cites work

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Guidelines for acromegaly management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Somatostatin analogs in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

The pharmacological aspects of the treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Estroprogestinic pill normalizes IGF-I levels in acromegalic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Somatostatin and its receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Dopamine resistance of prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Rational design of potent antagonists to the human growth hormone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Role of gamma knife radiosurgery in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Octreotide treatment does not affect the size of most non-functioning pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Clinical results of long-term slow-release lanreotide treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Current approaches to imaging of the sellar region and pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Diagnosis and treatment of acromegaly complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349183

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

21 January 2018

1 reference

12 December 2020

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

1 reference

12 December 2020

Current treatment guidelines for acromegaly

1 reference

12 December 2020

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

1 reference

12 December 2020

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

1 reference

12 December 2020

Volume of pituitary macroadenomas: assessment by MRI.

1 reference

12 December 2020

The volume of the sella turcica

1 reference

12 December 2020

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion

1 reference

12 December 2020

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

12 December 2020

Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment

1 reference

12 December 2020

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide

1 reference

12 December 2020

Factors influencing mortality in acromegaly

1 reference

12 December 2020

Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas

1 reference

12 December 2020

Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

Octreotide as primary therapy for acromegaly.

1 reference

12 December 2020

1 reference

12 December 2020

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03349183

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16553040%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference